Anticoagulation Safe for Patients with Brain Metastases

Share this content:
Anticoagulation Safe for Patients with Brain Metastases
Anticoagulation Safe for Patients with Brain Metastases

HealthDay News — Therapeutic anticoagulation is safe for treating venous thromboembolism in patients with brain metastases, according to a study published in Blood.

The study included 293 patients with brain metastases and venous thromboembolism. The patients were randomly selected to receive enoxaparin (Lovenox) or no anticoagulation medication.

After 12 months, the incidence of intracranial hemorrhage was 44% for people taking enoxaparin. In those who didn't take the medication, 37% experienced intracranial hemorrhage; however, this was not a statistically significant difference (P = 0.13). Overall survival was similar for both groups.

"While it is a very common clinical scenario to treat a patient with a metastatic brain tumor who also develops a blood clot, before this study there was very little data to inform the difficult decision of whether or not to anticoagulate these patients," senior author Jeffrey Zwicker, MD, of Beth Israel Deaconess Medical Center and Harvard Medical School in Boston, said in a news release from the American Society of Hematology. "Our findings, which demonstrate that current practice is safe, should reassure physicians that anticoagulants can be safely administered to patients with brain metastases and a history of blood clots."

Reference

  1. Donato J et al. Blood. 2015; doi:10.1182/blood-2015-02-626788. 
You must be a registered member of Neurology Advisor to post a comment.

Sign Up for Free e-newsletters

CME Focus